This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Terrapeutics Pharma


Terrapeutics is a drug discovery platform that developed an exciting technology that re-invents the lost art of discovering novel therapeutic molecules from soil-based microorganisms. While Industry leaders agree that molecules produced by soil-based bacteria can solve many therapeutic challenges, current methodologies can uncover only 0.1% of the potential. The staggering 99.9% are unexplored and considered "dark matter" to Pharma companies. Our groundbreaking discovery technology combines synthetic biology, sequencing tools, and bioinformatics utilizing soil's full potential to discover novel small molecules that can tackle undruggable targets. Our technology performs efficient drug target-based screening in soil to swiftly identify the specific drug producing bacteria (against a specific, pre-defined target) and the biosynthetic gene clusters associated with such activities. This ability allows us to have a solid basis for bio-manufacturing such molecules, to isolate, identify, and develop them into commercial drugs. Our lead program is to discover and develop pan KRAS inhibitors. We successfully discovered inhibitors producing bacteria and the biosynthetic gene clusters that regulate it, and we are now working on isolating these molecules. We recently finished the Illumina accelerator program, where we developed genomic tools to identify the biosynthetic gene clusters associated with producing drugs in soil-based screening. The company raised pre-seed funding from Illumina, a leading global life science industry figure and a US VC fund. Our advisory board comprises leading figures in academia, including Prof. Roger Kornberg, a Nobel Prize Laureate. We seek to raise our seed round and strategic collaborations to support our multi-program discovery and development pipeline.